S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|Celldex Therapeutics Establishes Preclinical Proof of Concept for New Antibody Drug Conjugate CDX-014; Data presented at AACR 2014 (2014/4/7)|
|Celldex Therapeutics to Present Antibody-Drug Conjugate CDX-014 Preclinical Proof of Concept Data at AACR 2014 (2014/4/3)|
|Celldex Reports Fiscal 2013 Business/Financial Results and Outlines 2014 Strategy (2014/3/3)|
|Celldex Therapeutics' CDX-1127 Well Tolerated and Demonstrates Anti-Tumor Activity in Phase 1 Dose-Escalation Study ()|
|Celldex Therapeutics' Rindopepimut Demonstrates Promising Clinical Activity in Patients with EGFRvIII-positive Recurrent Glioblastoma at SNO (2013/11/24)|
|Celldex Therapeutics Prices Public Offering of Common Stock (2013/12/4)|
|Celldex Therapeutics Initiates METRIC, an Accelerated Approval Study of Glembatumumab Vedotin in Patients with Triple Negative Breast Cancer ()|
|Celldex Therapeutics Announces Upcoming Presentation at the Leerink Swann Rare Disease Roundtable ()|
|Celldex Therapeutics Announces Publication of Preliminary Data from the Phase 2 ReACT Study to be Presented at the 18th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) (2013/11/11)|
|Celldex Therapeutics Announces Proposed Public Offering of Common Stock ()|
Click above to view more mutual fund data and stats for cldx - Celldex Therapeutics, Inc..